Clinical Trial Update: NATIENS: Optimal Management and Mechanisms of SJS/TEN [Phase 3]

View source ↗

Summary

Phase 3 clinical trial NATIENS for optimal management and mechanisms of Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Stevens-johnson Syndrome
• Toxic Epidermal Necrolysis

Snippet

Sponsor: Vanderbilt University Medical Center | Conditions: Stevens-Johnson Syndrome, Toxic Epidermal Necrolyses | Phase 3 | Status: COMPLETED